The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies
- PMID: 30397772
- DOI: 10.1007/s11864-018-0593-2
The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies
Abstract
Activity of PD-1 and PD-L1 inhibitors has been demonstrated in ovarian, endometrial, and cervical cancer, with a tolerable side effect profile and the highest response rate seen in mismatch repair-deficient endometrial cancers. Other biomarkers are under active investigation. Tumor testing for mismatch repair deficiency or high microsatellite instability for treatment with pembrolizumab should be considered an option for all women with progressive gynecologic malignancy.
Keywords: Cervical cancer; Endometrial cancer; Gynecologic cancer; Immunotherapy; Ovarian cancer; Programmed death ligand-1.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
